Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 99.95 -1.40 (-1.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Ligand Distribution of OmniAb Complete and Business Combination Closed November 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report Third Quarter Financial Results on November 7 October 26, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma October 26, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Stocks That Hit 52-Week Lows On Wednesday February 23, 2022 On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... Via Benzinga Earnings Scheduled For February 17, 2022 February 17, 2022 Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. Via Benzinga OmniAb Business Combination Approved by APAC Shareholders October 24, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 03, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off October 03, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients August 25, 2022 Via Benzinga Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary August 24, 2022 Via Benzinga Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma August 24, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals: Q2 Earnings Insights August 08, 2022 Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals... Via Benzinga Ligand Reports Second Quarter 2022 Financial Results August 08, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report Second Quarter Financial Results on August 8 July 22, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know July 05, 2022 Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%... Via Benzinga Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors June 29, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire 10 Biggest Price Target Changes For Monday May 16, 2022 Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. Via Benzinga Ligand Reports First Quarter 2022 Financial Results May 04, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report First Quarter Financial Results on May 4 April 19, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 08, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL March 24, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger March 24, 2022 Ligand Pharmaceuticals Inc (NASDAQ: LGND) Via Benzinga Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II March 23, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Tough Slogging Ahead for Investors, Diversification is Important March 07, 2022 Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. Via Talk Markets Recap: Ligand Pharmaceuticals Q4 Earnings February 17, 2022 Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Via Benzinga Ligand Reports Fourth Quarter and Full Year 2021 Financial Results February 17, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios February 17, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... Via Benzinga The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More February 13, 2022 Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... Via Benzinga Ligand to Report Fourth Quarter Financial Results on February 17 February 09, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.